

“A vaccine for Alzheimer’s disease could be trialed in humans within the next 3-5 years, after researchers from the United States and Australia have uncovered a formulation that they say successfully targets brain proteins that play a role in development and progression of the disease.”
“Study co-author Prof. Nikolai Petrovsky, of Flinders University School of Medicine in Australia, and colleagues reveal how a vaccine combination generates antibodies that target beta-amyloid and tau proteins in the brain – both of which are considered hallmarks of Alzheimer’s disease. Beta-amyloid is known to accumulate in the brains of people with Alzheimer’s, forming plaques, while the tau protein forms tangles. Plaques and tangles are believed to disrupt signaling between nerve cells and contribute to nerve cell death.”
Read the full article: Alzheimer’s vaccine steps closer with new study
Recent Posts
- The American Health Council Appoints Dr. James Bashkin, D.Phil. to the Physician Board March 31, 2020
- The American Health Council Appoints Dr. Robert W. Letton, MD to the Physician Board March 19, 2020
- The American Health Council Appoints Dr. Akwasi Adjei to the Industry Board January 17, 2020
- The American Health Council Appoints Dr. Nelson Leung to the Physician Board January 17, 2020
- The American Health Council Appoints Ms. Karie Soost to the Physician Board January 17, 2020
- The American Health Council Appoints Mr. Gregory King to the Industry Board January 17, 2020